Ovid Therapeutics Inc.

For the period ended Jun 30, 2026. Filed Aug 13, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 13, 2026

OVID$2.80-1.8%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity

Condensed Consolidated Statements of Stockholders’ Equity (unaudited)

(in thousands, except shares) · Series AConvertiblePreferred Stock · Common Stock · AdditionalPaid-In Capital · Accumulated Other Comprehensive Loss · Accumulated Deficit · Total
Shares · Amount · Shares · Amount
Balance, December 31, 2025	—		$—		130,184,353		$130		$452,445	$(202)	$(321,713)	$130,660
Issuance of shares of common stock sold under the ATM program, net of expenses	—		—		1,500,000		2		2,365	—	—	2,367
Issuance of shares of common stock and pre-funded warrants from private placement financing	—		—		19,154,321		19		59,981	—	—	60,000
Expenses related to the issuance of shares of common stock and pre-funded warrants from private placement financing	—		—		—		—		(3,816)	—	—	(3,816)
Exercise of Series A warrants to shares of common stock and pre-funded warrants	—		—		16,140,663		16		26,577	—	—	26,593
Expenses related to the exercise of Series A warrants to shares of common stock and pre-funded warrants	—		—		—		—		(1,593)	—	—	(1,593)
Issuance of shares of common stock from exercise of stock options, employee stock purchase plan and vesting of RSU awards	—		—		287,129		—		220	—	—	220
Stock-based compensation expense	—		—		—		—		1,046	—	—	1,046
Other comprehensive loss	—		—		—		—		—	(220)	—	(220)
Net loss	—		—		—		—		—	—	(16,988)	(16,988)
Balance, March 31, 2026	—		$—		167,266,466		$167		$537,225	(422)	$(338,701)	$198,269
Exercise of Series A warrants to shares of common stock and pre-funded warrants	—		—		17,457,197		18		27,276	—	—	27,294
Expenses related to the exercise of Series A warrants to shares of common stock and pre-funded warrants	—		—		—		—		(1,774)	—	—	(1,774)
Issuance of shares of common stock from exercise of stock options, employee stock purchase plan and vesting of RSU awards	—		—		32,072		—		7	—	—	7
Stock-based compensation expense	—		—		—		—		1,431	—	—	1,431
Other comprehensive loss	—		—		—		—		—	(328)	—	(328)
Net loss	—		—		—		—		—	—	(15,009)	(15,009)
Balance, June 30, 2026	—		$—		184,755,735		$185		$564,165	$(750)	$(353,710)	$209,890
(in thousands, except shares)	Series AConvertiblePreferred Stock	Common Stock		AdditionalPaid-In Capital	AccumulatedOtherComprehensive Loss	Accumulated Deficit		Total
Shares · Amount · Shares · Amount
Balance, December 31, 2024	1,250		$—		71,009,866		$71		$372,489	$(35)	$(304,299)	$68,226
Issuance of common stock from exercise of stock options, employee stock purchase plan and vesting of RSU awards	—		—		99,648		—		13	—	—	13
Stock-based compensation expense	—		—		—		—		1,284	—	—	1,284
Other comprehensive loss	—		—		—		—		—	(12)	—	(12)
Net loss	—		—		—		—		—	—	(10,235)	(10,235)
Balance, March 31, 2025	1,250		$—		71,109,514		$71		$373,786	(47)	$(314,534)	$59,276
Stock-based compensation expense	—		—		—		—		1,219	—	—	1,219
Other comprehensive loss	—		—		—		—		—	(22)	—	(22)
Net loss	—		—		—		—		—	—	(4,684)	(4,684)
Balance, June 30, 2025	1,250		$—		71,109,514		$71		$375,005	$(69)	$(319,218)	$55,789

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.